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Cancer patients aged 15–24 years have distinct special needs. High quality cancer statistics are required for service planning.
Data presented by primary site are inappropriate for this age group. We have developed a morphology-based classiﬁcation
and applied it to national cancer registration data for England 1979–1997. The study included 25000 cancers and 134 million
person–years at risk. Rates for each diagnostic group by age, sex and time period (1979–83, 1984–87, 1988–92, 1993–
1997) were calculated. Overall rates in 15–19 and 20–24-year-olds were 144 and 226 per million person–years
respectively. Lymphomas showed the highest rates in both age groups. Rates for leukaemias and bone tumours were lower in
20–24 year olds. Higher rates for carcinomas, central nervous system tumours, germ-cell tumours, soft tissue sarcomas and
melanoma were seen in the older group. Poisson regression showed incidence increased over the study period by an average
of 1.5% per annum (P50.0001). Signiﬁcant increases were seen in non-Hodgkins lymphoma (2.3%), astrocytoma (2.3%),
germ-cell tumours (2.3%), melanoma (5.1%) and carcinoma of the thyroid (3.5%) and ovary (3.0%). Cancers common in the
elderly are uncommon in adolescents and young adults. The incidence of certain cancers in the latter is increasing. Future
studies should be directed towards aetiology.
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The National Health Service Cancer Plan, aims to improve survival
rates by delivering the best and most appropriate treatment for
each individual patient (Department of Health, 2000). An impor-
tant element in achieving this aim is the availability of high
quality population-based cancer statistics. In the United Kingdom
such data are available through national cancer registration (Quinn
et al, 2001; Walsh et al, 2001; http//www.show.scot.nhs.uk/isd/
cancer/cancer.htm). One important group of cancer patients with
special needs is those diagnosed during adolescence and young
adulthood. While a co-ordinated approach to the treatment of
cancers in children has been established for many years adolescents
and young adults have fared less well (Bleyer, 2002). Cancers in
this age group, even if cured, can have a devastating effect on
future life including the development of second cancers (Bleyer,
2002). In order to develop services tailored to their needs, it is
necessary to deﬁne the extent and nature of the patient population
through precise analyses of relevant population-based data.
Cancer incidence data are usually presented in terms of primary
site according to the International Classiﬁcation of Diseases (ICD)
(World Health Organisation, 1975, 1992; Parkin et al, 1997). This
is broadly satisfactory for late age of onset, cancers which are
mainly carcinomas, but in young people carcinomas are much less
important numerically. For epidemiological and service planning
purposes, data on cancers in young people should be presented
mainly in terms of morphology. The aims of the present study
were to develop a diagnostic classiﬁcation scheme appropriate to
cancers in young persons and to apply the scheme to national
cancer registration data to give an accurate and balanced picture
of cancers in this age group.
METHODS
Anonymised individual level national cancer registration data for
the years 1971 to 1992 were obtained on CD-ROM (Quinn et al,
1999). More recent data up to 1997 were supplied directly by
the Ofﬁce for National Statistics (ONS). It has been demonstrated
that there was probably some under-registration during the early
1970s but, from the late 1970s onwards registration has been
largely complete and consistent (Quinn et al, 2001). Because of
these considerations, data for the years 1979 to 1997 were analysed
for the present study. Furthermore, in earlier years, data were
coded in MOTNAC (American Cancer Society, 1968) which trans-
lates very imperfectly into the proposed classiﬁcation. From 1979
to 1994 data are coded by ICD-O ﬁrst edition (World Health
Organisation, 1976) and ICD ninth revision (World Health Orga-
nisation, 1975) and from 1995 onwards by ICD-O second edition
(Percy et al, 1990) and ICD tenth revision (World Health Organi-
sation, 1992). National population estimates by single year of age,
sex and calendar year were supplied by the Population Estimates
Unit, ONS.
Construction of the classiﬁcation scheme
For registered cancers in the age range 15 to 24 years, frequency
tables by individual ICD-O M-code were produced. These tables
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www.bjcancer.comwere used to formulate groupings of M-codes to create main diag-
nostic groups. In deﬁning the groups, the following principles were
applied: (1) the groupings should reﬂect the numerical importance
of speciﬁc cancers; (2) common cancers should be speciﬁed as
individual categories; (3) rare tumours of particular interest should
also form speciﬁc categories; (4) categories should be based princi-
pally on morphology with biologically similar tumours classiﬁed
together; and (5) diagnostic categories should be hierarchical to
allow maximum ﬂexibility in analyses.
Statistical analyses
Eligible cases included all malignant tumours, except carcinomas of
skin, occurring in England from 1979 to 1997 in individuals aged 15
to 24 years. In situ cancers and neoplasms of uncertain behaviour
were excluded. Scrutiny of the data for non-malignant central
nervous system (CNS) tumours suggested that there were variations
in registration practices between regional cancer registries, so only
malignant CNS tumours were included in the analyses.
Individual cancer registrations were classiﬁed by; cancer type, age
group (15to 19, 20–24 years), sex and timeperiod (1979–83, 1984–
87, 1988–92, 1993–97). These time periods were chosen to give the
most even distribution of person–years at risk. The person–years at
risk for each sub-group were calculated from the population data.
Age group, sex and diagnostic period speciﬁc annual incidence rates
per million population were calculated. Age-speciﬁc rates for the 15–
19-year-olds and 20–24-year-olds were calculated. An age-standar-
dised rate was calculated at each time period, using direct
standardisation to the world population (Parkin et al, 1997). A
combined rate for the entire time span was obtained using a weighted
average of the separate standardised rates (Blair and Birch, 1994). The
signiﬁcance of variability by sex, age group and time period was
assessed using Poisson regression. Changes in the incidence rate over
time were assessed after taking into account variability in cancer rates
by age and sex. It was assumed that the changes in incidence rates
over time were consistent. All calculations were performed using
the statistical package GLIM 4 (Francis et al, 1993).
RESULTS
The classiﬁcation scheme
Ten main cancer groups were deﬁned, each of which (except group
10, unspeciﬁed) is divided into sub-groups giving 32 in all. Fifteen
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Table 1 Classiﬁcation scheme for cancers in adolescents and young
adults
Group 1 – Leukaemias
1.1. Acute lymphoid leukaemia (ALL)
1.2. Acute myeloid leukaemia (AML)
1.3. Chronic myeloid leukaemia (CML)
1.4. Other and uspeciﬁed leukaemia (Other Leuk)
1.4.1. Other and unspeciﬁed lymphoid leukaemias
1.4.2. Other and unspeciﬁed myeloid leukaemias
1.4.3. Other speciﬁed leukaemias, NEC
1.4.4. Unspeciﬁed leukaemia
Group 2 – Lymphomas
2.1. Non-Hodgkin’s lymphoma (NHL)
2.1.1. Non-Hodgkin’s lymphoma, speciﬁed subtype
2.1.2. Non-Hodgkin’s lymphoma, subtype not speciﬁed
2.2. Hodgkin’s disease (HD)
2.2.1. Hodgkin’s disease, speciﬁed subtype
2.2.2. Hodgkin’s disease, subtype not speciﬁed
Group 3 – Central nervous system and other intracranial and intraspinal neoplasms
(CNS tumours)
3.1. Astrocytoma
3.1.1. Speciﬁed low grade astrocytoma
3.1.2. Glioblastoma and anaplastic astrocytoma
3.1.3. Astrocytoma not otherwise speciﬁed
3.2. Other gliomas
3.3. Ependymoma
3.4. Medulloblastoma and other primitive neuroectodermal tumours
(Medulloblastoma)
3.5. Other and unspeciﬁed malignant intracranial and intraspinal neoplasms
(Other CNS)
3.5.1. Other speciﬁed malignant intracranial and intraspinal neoplasms
3.5.2. Unspeciﬁed malignant intracranial and intraspinal neoplasms
3.6. Non-malignant intracranial and intraspinal neoplasms
3.6.1. Speciﬁed non-malignant intracranial or intraspinal neoplasms
3.6.2. Unspeciﬁed intracranial or intraspinal neoplasms
Group 4 – Osseous and chondromatous neoplasms, Ewings tumour and other neoplasms
of bone (bone tumours)
4.1. Osteosarcoma
4.2. Chondrosarcoma
4.3. Ewing’s tumour
4.4. Other speciﬁed and unspeciﬁed bone tumours (Other bone tumours)
4.4.1. Other speciﬁed bone tumours
4.4.2. Unspeciﬁed bone tumours
Group 5 – Soft tissue sarcomas (STS)
5.1. Fibromatous neoplasms (Fibrosarcoma)
5.2. Rhabdomyosarcoma
5.3. Other soft tissue sarcomas
5.3.1. Other speciﬁed soft tissue sarcomas
5.3.2. Unspeciﬁed soft tissue sarcomas
Group 6 – Germ cell and trophoblastic neoplasms (germ cell tumours)
6.1. Gonadal germ cell and trophoblastic neoplasms
6.2. Germ cell and trophoblastic neoplasms of non-gonadal sites
6.2.1. Intracranial germ cell and trophoblastic tumours
6.2.2. Other non-gonadal germ cell and trophoblastic tumours
Group 7 – Melanoma and skin carcinoma
7.1. Melanoma
7.2. Skin carcinoma
Group 8 – Carcinomas (except of skin)
8.1. Carcinoma of thyroid
8.2. Other carcinoma of head and neck
8.2.1. Nasopharyngeal carcinoma
8.2.2. Carcinoma of other sites in lip oral cavity and pharynx
8.2.3. Carcinoma of nasal cavity, middle ear, sinuses, larynx and other
ill-deﬁned sites in head and neck
8.3. Carcinoma of trachea, bronchus, lung and pleura
8.4. Carcinoma of breast
8.5. Carcinoma of genito-urinary (GU) tract
8.5.1. Carcinoma of kidney
8.5.2. Carcinoma of bladder
Continued
8.5.3. Carcinoma of ovary and testis
8.5.4. Carcinoma of cervix and uterus
8.5.5. Carcinoma of other and ill-deﬁned sites in GU
8.6. Carcinoma of gastro-intestinal (GI) tract
8.6.1. Carcinoma of colon and rectum
8.6.2. Carcinoma of stomach
8.6.3. Carcinoma of liver and ill-deﬁned sites in GI tract
8.7. Carcinomas of other and ill-deﬁned sites not elsewhere classiﬁed (NEC)
8.7.1. Adrenocortical carcinoma
8.7.2. Other carcinomas NEC
Group 9 – Miscellaneous speciﬁed neoplasms NEC
9.1. Embryonal tumours NEC
9.1.1. Wilms tumour
9.1.2. Neuroblastoma
9.1.3. Other embryonal tumours NEC
9.2. Other rare miscellaneous speciﬁed neoplasms
9.2.1. Paraganglioma and glomus tumours
9.2.2. Other speciﬁed gonadal tumours NEC
9.2.3. Myeloma, mast cell tumours and miscellaneous reticuloendothelial
neoplasms NEC
9.2.4 Other speciﬁed neoplasms NEC
Group 10 – Unspeciﬁed malignant neoplasms NEC
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British Journal of Cancer (2002) 87(11), 1267–1274 ã 2002 Cancer Research UKof the sub-groups are further sub-divided, thereby providing three
levels of classiﬁcation. The classiﬁcation scheme is shown in Table
1. Each main group and each level of sub-group are speciﬁed by
combinations of ICD-O (eds.1 & 2) M-codes and topography
codes (T code). For example, cases with the morphology code
8800/3 (sarcoma not otherwise speciﬁed) are classiﬁed with bone
tumours if combined with a T-code in the range C40.0–C41.9
(bones, joints and articular cartilage) but if combined with any
other T-code, these cases are classiﬁed with soft tissue sarcomas.
The group-speciﬁc M and T code allocations together with respec-
tive algorithms for selecting tumour groups are given at: (http://
www.biomed2.man.ac.uk/crcpfcrg/CRUKPFCRG/PFCRG.htm).
As in published childhood cancer classiﬁcation schemes based
on ICD-O ﬁrst and second editions (Birch and Marsden, 1987;
Krama ￿rova ￿ and Stiller, 1996), leukaemias, lymphomas and CNS
tumours constitute the ﬁrst three major groups. However, non-
CNS embryonal tumours including neuroblastoma, retinoblastoma,
Wilms’ tumour and hepatoblastoma, which form the major
components of groups IV, V, VI and VII in the childhood classiﬁ-
cations, are extremely rare over the age of 15 years. All of these
tumours are therefore grouped together under Miscellaneous Speci-
ﬁed Neoplasms NEC (Table 1, Group 9).
Bone and soft tissue sarcomas, as in childhood, represent
numerically important malignancies in adolescents and young
adults and these tumours form Groups 4 and 5. In the childhood
cancer classiﬁcations, extra-skeletal Ewing’s tumour and other
extra-skeletal peripheral primitive neuroectodermal tumours are
classiﬁed with soft tissue sarcomas but in the proposed classiﬁca-
tion for cancers in adolescents and young adults, we have
grouped all Ewing’s and related tumours together regardless of
coded primary site. There are two reasons for this: ﬁrstly, morpho-
logically and biologically such tumours are all similar and are
characterised by the presence of the Fli-l;EWS fusion gene
(Parham, 1996) and secondly, even with full clinical information
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Table 2 Observed numbers of cancers in persons aged 15–24 years in England, 1979–1997
Age groups (years)
15–19 20–24 15–24
M F M F Total %
Leukaemias 909 546 729 485 2669 10.7
ALL 548 265 296 131 1240 5.0
AML 260 197 280 262 999 4.0
CML 47 33 95 52 227 0.9
Other leukaemia 54 51 58 40 203 0.8
Lymphomas 1457 1104 2098 1682 6341 25.5
NHL 518 237 649 340 1744 7.0
HD 939 867 1449 1342 4597 18.5
CNS tumours 559 450 707 505 2221 8.9
Astrocytoma 282 252 331 259 1124 4.5
Other glioma 109 82 193 116 500 2.0
Ependymoma 42 23 45 35 145 0.6
Medulloblastoma 57 39 66 39 201 0.8
Other CNS 69 54 72 56 251 1.0
Bone tumours 543 346 342 180 1411 5.7
Osteosarcoma 307 189 153 72 721 2.9
Chondrosarcoma 30 23 42 23 118 0.5
Ewing’s tumour 167 98 109 50 424 1.7
Other bone tumours 39 36 38 35 148 0.6
Soft tissue sarcomas 336 245 390 368 1339 5.4
Fibrosarcoma 61 52 106 100 319 1.3
Rhabdomyosarcoma 129 72 52 46 299 1.2
Other STS 146 121 232 222 721 2.9
Germ cell tumours 687 182 2382 175 3426 13.8
Gonadal 610 154 2294 128 3186 12.8
Non-gonadal 77 28 88 47 240 1.0
Melanoma 197 330 520 1043 2090 8.4
Carcinomas 397 635 806 2434 4272 17.1
Thyroid 52 209 112 430 803 3.2
Other head and neck 105 69 113 107 394 1.6
Lung 12 13 46 34 105 0.4
Breast 2 36 1 354 393 1.6
GU tract 58 154 200 1187 1599 6.4
GI tract 111 101 230 227 669 2.7
Other carcinomas 57 53 104 95 309 1.2
Miscellaneous, speciﬁed 57 69 64 88 278 1.1
Unspeciﬁed 126 132 302 292 852 3.4
All cancers* 5268 4039 8340 7252 24899 100.0
Years at risk (thousands) 33268 31268 35184 33849 133786
*Excludes skin carcinoma.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(11), 1267–1274it is often difﬁcult to determine the origin of such tumours and
not possible to ascertain whether a tumour is arising in bone
and invading soft tissue or vice versa. In practice the extra-skeletal
tumours of the Ewing’s family are rare and make little difference to
the overall rates.
A similar argument can be made for grouping all malignant
ﬁbrous histiocytomas (MFH) together. Very rarely, MFH can arise
in bone but in the proposed classiﬁcation all cases classiﬁed
morphologically as MFH are grouped with ﬁbromatous neoplasms
(Group 5.1). Malignant peripheral nerve sheath tumours (MPNST)
are included with other speciﬁed soft tissue sarcomas (Group
5.3.1). In the childhood classiﬁcations, MPNST was included with
ﬁbromatous neoplasms but this is inconsistent with current classi-
ﬁcations and with the histogenetic origin of these tumours (Weiss
and Goldblum, 2001).
Group 6 comprises malignant germ cell tumours. Although
germ cell tumours form a separate group in the childhood classi-
ﬁcations they represent approximately 3% only of total
childhood cancers (McNally et al, 2001a). In the 15–24 year age
group, germ cell tumours are much more numerous and in the
present series, constitute approximately 14% of the total cancers.
Similarly, malignant melanoma, which is very rare in children,
represents a important group in adolescents and young adults both
numerically and clinically and is included in Group 7. One of the
main failings of the childhood cancer classiﬁcation with respect to
its application to young adult cancers is the lack of detail and the
inappropriate sub-groupings of carcinomas. The proposed classiﬁ-
cation employs a more detailed treatment of carcinomas (Group
8).
Table 2 shows the numbers of cases included in the study clas-
siﬁed according to main group and ﬁrst level of sub-group, by age
group and sex. There were almost 25000 eligible cases and the
study covered nearly 134 million person–years at risk.
Cancer rates by age and sex
Table 3 shows the incidence rates per million person–years for
each age group in males and females by diagnostic group. Overall
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Table 3 Cancer incidence rates per million years at risk in persons aged 15–24 years in England, 1979–1997
Age group (years)
15–19 20–24 Signiﬁcance level
a
M F M+F M F M+F Age Sex Interaction
Leukaemias 27.3 17.3 22.5 20.7 14.3 17.6
ee
ALL 16.5 8.4 12.6 8.4 3.9 6.2
ee
AML 7.8 6.3 7.1 8.0 7.7 7.9
CML 1.4 1.0 1.2 2.7 1.5 2.1
ed
Other leukaemias 1.6 1.6 1.6 1.6 1.2 1.4
Lymphomas 43.8 35.1 39.5 59.6 49.7 54.8
ee
NHL 15.6 7.5 11.7 18.4 10.0 14.3
ee
HD 28.2 27.5 27.9 41.2 39.6 40.4
e
CNS tumours 16.8 14.3 15.6 20.1 14.9 17.6
de
Astrocytoma 8.5 8.0 8.2 9.4 7.7 8.5
b
Other glioma 3.3 2.6 2.9 5.5 3.4 4.5
ee
Ependymoma 1.3 0.7 1.0 1.3 1.0 1.2
b
Medulloblastoma 1.7 1.2 1.5 1.9 1.2 1.5
c
Other CNS 2.1 1.7 1.9 2.0 1.7 1.9
Bone tumours 16.3 11.0 13.7 9.7 5.3 7.6
ee
Osteosarcoma 9.2 6.0 7.7 4.3 2.1 3.3
ee
Chondrosarcoma 0.9 0.7 0.8 1.2 0.7 0.9
b
Ewing’s sarcoma 5.0 3.1 4.1 3.1 1.5 2.3
ee
Other bone tumours 1.2 1.1 1.2 1.1 1.0 1.1
Soft tissue sarcomas 10.1 7.8 9.0 11.1 10.9 11.0
db b
Fibrosarcoma 1.8 1.7 1.7 3.0 3.0 3.0
d
Rhabdomyosarcoma 3.9 2.3 3.1 1.5 1.4 1.4
ec
Other STS 4.4 3.8 4.1 6.6 6.6 6.6
e
Germ cell tumours 20.7 5.8 13.4 67.7 5.2 37.0
ee e
Gonadal 18.3 4.9 11.8 65.2 3.8 35.1
ee e
Non-gonadal 2.3 0.9 1.6 2.5 1.4 2.0
e
Melanoma 5.9 10.5 8.1 14.8 30.8 22.6
ee
Carcinomas 11.9 20.2 15.9 22.9 71.9 46.9
ee e
Thyroid 1.6 6.6 4.0 3.2 12.7 7.9
ee
Other head and neck 3.2 2.2 2.7 3.2 3.2 3.2
Lung 0.4 0.4 0.4 1.3 1.0 1.2
e
Breast 0.1 1.1 0.6 0.0 10.5 5.1
ee b
GU tract 1.7 4.9 3.3 5.7 35.1 20.1
ee e
GI tract 3.3 3.2 3.3 6.5 6.7 6.6
e
Other carcinomas 1.7 1.7 1.7 3.0 2.8 2.9
e
Miscellaneous, speciﬁed 1.7 2.2 1.9 1.8 2.6 2.2
b
Unspeciﬁed 3.8 4.2 4.0 8.6 8.6 8.6
e
All 158 128 144 238 214 226
ee e
aSigniﬁcance levels;
bP=50.05;
cP=50.01;
dP=50.001;
eP=50.0001.
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British Journal of Cancer (2002) 87(11), 1267–1274 ã 2002 Cancer Research UKrates in both males and females were signiﬁcantly higher at 20 to
24 years than at 15 to 19 years (P50.0001) and rates were signiﬁ-
cantly higher in males than in females in both age groups
(P50.0001). There was however, some variation in the pattern
according to diagnostic group. Among leukaemias, rates were high-
er in males than in females. The incidence of ALL in 15 to 19 year
olds was twice that in 20 to 24 year olds. ALL is one of only two
groups to show this pattern (see below). For AML the rates are
similar in both age groups, but CML has higher rates at older ages.
Rates for lymphomas were signiﬁcantly higher in the older age
group particularly for HD. For NHL, rates in males were signiﬁ-
cantly higher than in females but rates for HD were similar in
both sexes.
Rates for CNS tumours were higher for males aged 20 to 24
years than 15 to 19 years but not for females. The only individual
sub-group to show signiﬁcantly higher rates in the older age group
was the ‘other gliomas’. CNS tumours had higher rates in males
than in females. Bone tumours form the other group showing a fall
in rates at older compared with younger ages. This pattern was
apparent in both osteosarcoma and Ewing’s tumour. Rates for
bone tumours were signiﬁcantly higher in males than in females.
Overall, soft tissue sarcomas had higher rates among the 20 to
24 year olds, but rates for rhabdomyosarcoma were signiﬁcantly
higher at younger ages. The biggest difference in rates between
the younger and older age groups was seen for germ cell tumours
in males (20.7 and 67.7 respectively). This was entirely accounted
for by testicular tumours.
In contrast to the ﬁrst six cancer groups, where rates were high-
er in males, rates in the last four groups were consistently higher in
females. Highly signiﬁcant increases in rates between the younger
and older groups were seen for melanoma and carcinomas. This
pattern was present for all the sub-groups of carcinomas but was
most marked for carcinomas of breast and GU sites, where the
ratio between rates in the older and the younger groups were 8.7
and 6.1 respectively. GU carcinomas were further examined by
sub-type: differences in rates between age groups were 3–4-fold
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Table 4 Age-standardized incidence rates per million years at risk in persons aged 15–24 years in England 1979–1997 by time
period
Rate per million person years at risk
79–83 84–87 88–92 93–97 All P value
a Change (95% CI)
f
Leukaemia 19.0 20.4 20.8 20.6 20.2 0.6 (70.1, 1.3)
ALL 9.1 10.1 9.6 9.5 9.6 0.2 (70.9, 1.2)
AML 6.6 7.7 7.4 8.1 7.4
b 1.3 (0.1, 2.5)
CML 1.5 1.6 1.8 1.7 1.7 0.8 (71.7, 3.3)
Other leukaemia 1.7 1.0 2.0 1.3 1.5 70.4 (73.0, 2.2)
Lymphoma 43.4 46.8 49.9 46.6 46.7
c 0.7 (0.2, 1.2)
NHL 10.6 12.2 15.0 13.9 12.9
e 2.3 (1.3, 3.2)
HD 32.9 34.6 34.9 32.8 33.8 0.1 (70.5, 0.7)
CNS tumours 14.7 15.6 18.7 17.1 16.5
d 1.4 (0.6, 2.2)
Astrocytoma 7.1 7.9 9.1 9.6 8.4
e 2.3 (1.2, 3.4)
Other glioma 4.0 4.2 3.6 2.8 3.7
c 72.3 (74.0, 70.7)
Ependymoma 0.9 1.1 1.1 1.3 1.1 2.6 (70.6, 5.8)
Medulloblastoma 1.4 1.2 1.6 1.7 1.5 1.9 (70.7, 4.7)
Other CNS 1.3 1.2 3.3 1.7 1.9
d 4.1 (1.7, 6.6)
Bone tumours 10.2 10.9 10.7 11.6 10.8 0.8 (70.2, 1.8)
Osteosarcoma 5.4 5.8 5.0 6.2 5.6 0.5 (70.9, 1.9)
Chondrosarcoma 0.8 1.1 0.8 0.7 0.9 71.1 (74.4, 2.4)
Ewing’s tumour 3.0 3.0 3.3 3.7 3.3 1.6 (70.2, 3.5)
Other bone tumours 0.9 1.1 1.5 1.0 1.1 1.4 (71.7, 4.6)
Soft tissue sarcomas 9.2 10.4 10.7 9.5 9.9 0.4 (70.6, 1.4)
Fibrosarcoma 2.7 2.8 2.2 1.6 2.3
c 73.5 (75.5, 71.4)
Rhabdomyosarcoma 2.0 2.8 2.4 2.2 2.3 0.4 (71.8, 2.6)
Other STS 4.5 4.8 6.1 5.7 5.3
c 2.1 (0.7, 3.6)
Germ cell tumours 20.8 23.8 24.6 29.6 24.5
e 2.3 (1.7, 3.0)
Gonadal 19.2 22.3 22.7 27.3 22.8
e 2.3 (1.6, 3.0)
Non-gonadal 1.6 1.5 1.9 2.2 1.8
b 2.5 (0.0, 5.0)
Melanoma 10.0 13.2 17.0 20.2 15.0
e 5.1 (4.3, 6.0)
Carcinoma 29.9 30.5 27.9 34.0 30.5
b 0.7 (0.1, 1.3)
Thyroid 4.8 5.4 5.5 7.8 5.8
e 3.5 (2.1, 4.9)
Other head and neck 3.3 2.6 2.6 3.1 2.9 70.4 (72.3, 1.5)
Lung 0.9 0.6 0.7 0.8 0.7 71.6 (75.1, 2.1)
Breast 2.5 2.8 2.9 2.7 2.7 0.9 (71.0, 2.9)
GU tract 10.5 11.7 10.0 12.9 11.2
c 1.1 (0.1, 2.0)
GI tract 5.1 5.1 4.2 5.1 4.8 70.6 (72.0, 0.9)
Other carcinomas 2.9 2.3 2.0 1.7 2.3
d 73.6 (75.7, 71.5)
Miscellaneous, speciﬁed 2.1 2.1 2.1 1.9 2.1 70.6 (72.8, 1.6)
Unspeciﬁed 2.4 4.2 12.1 5.6 6.2
e 7.0 (5.5, 8.4)
All 162 178 195 197 182
e 1.5 (1.3, 1.7)
aP values for trend:
b50.05;
c50.01;
d50.001;
e50.0001.
fEstimated annual % increase in rate with 95% conﬁdence interval (CI). Negative values
indicate a decrease.
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difference was in carcinoma of the uterine cervix which increased
from 0.8 per million in 15 to 19 year olds to 21 per million in
20 to 24-year-olds.
Temporal trends in incidence
Table 4 presents time trends in incidence rates for the whole age
group (15 to 24 years). Across all diagnostic groups there was a
highly signiﬁcant increase in incidence rates over time
(P50.0001), although there was little difference between the third
and fourth time periods. Rates for leukaemias overall remained
stable over the study period, but AML showed a small increase.
Lymphomas overall showed a signiﬁcant increase which was
entirely accounted for by NHL.
Rates for CNS tumours increased over time. Among sub-groups
of brain tumours, astrocytoma and ‘other CNS’ tumours showed
increases but the ‘other glioma’ group showed a signiﬁcant
decrease. Rates for all bone tumours did not change during the
study period. Rates for soft tissue sarcomas overall, and for rhab-
domyosarcoma also did not change but rates for ﬁbrosarcoma
decreased, while the incidence of other soft tissue sarcomas
increased.
Very marked increases in incidence were seen for gonadal germ
cell tumours, melanoma and carcinoma of the thyroid. The
increase in gonadal germ cell tumours was accounted for by testi-
cular tumours (average annual percentage increase 9.5, 95% CI 3.1,
16.3; P for trend 50.0001). There was no corresponding increase
in ovarian germ cell tumours (P=0.2).
There was a small but signiﬁcant increase in rates for GU tract
carcinomas. Further examination of this latter group showed that
the increase was mainly due to ovarian carcinoma (average annual
percentage increase 3.0, 95% CI 1.2, 4.9; P=0.001).
The rates for melanoma include melanoma of skin and non-skin
sites mainly ocular (67 cases). The observed increase in incidence
was entirely due to melanoma of skin and was consistent across
both age groups and both sexes. The pattern of melanoma of skin
in males and females was examined according to primary site (head
and neck, trunk, upper limbs, lower limb). There was a highly
statistically signiﬁcant interaction between site and sex,
(P50.0001). Males had a slightly higher rate of head and neck
melanoma but females had a higher rate of trunk melanoma and
much higher rates of limb (particularly lower limb) melanoma.
Rates for melanoma of skin of lower limb were 2.6 per million
in males and 9.1 per million in females. The relative changes in site
distribution of melanoma over time did not reach statistical signif-
icance (P=0.06).
Carcinomas of other and ill-deﬁned sites showed a decrease in
incidence over time which is probably due to improvements in
the quality of cancer registration, but the numbers are relatively
small and do not account for the observed increases in speciﬁed
groups of carcinomas. Unspeciﬁed malignant neoplasms NEC
(Group 10) showed a signiﬁcant increase in incidence over time
and rates during 1988–92 were particularly high. More than one
third of all cases in this group were coded to G.U. sites. The most
frequent site was testis. It is likely that the majority of these would
be germ cell tumours. The reason for this large number of unspe-
ciﬁed registrations during this period is unclear but registrations
originally by death certiﬁcate, which were retrospectively allocated
to a year of diagnosis, may be a contributory factor (Quinn et al,
2001).
DISCUSSION
The need for a morphology-based classiﬁcation system for presen-
tation of data on cancers in children was recognised some time ago
(Birch and Marsden, 1987; Krama ￿rova ￿ and Stiller, 1996). This
childhood cancer classiﬁcation has been applied to cancer inci-
dence data in adolescents aged 15 to 19 years (Smith et al,
1999). However, this is not appropriate, since a number of the
major childhood cancer groups are irrelevant in adolescents and
young adults. Conversely, carcinomas, as speciﬁed in the childhood
cancer classiﬁcation, are inappropriately sub-divided and do not
describe the pattern observed in young adults adequately (Fritschi
et al, 1995). While leukaemias and lymphomas can be deﬁned by
ICD it is not possible to deﬁne soft tissue sarcomas and germ cell
tumours, which arise in many different anatomical sites and ICD
cannot distinguish non-epithelial cancers from carcinomas or
different types of these from each other. For example, carcinomas,
soft tissue sarcomas and germ cell tumours arising in the liver
would all be allocated the code for malignant neoplasm of liver.
Furthermore, there are important differences in the incidence
patterns of morphological sub-types of CNS and bone tumours.
Given these difﬁculties, Bleyer (2002) has suggested that a separate
nosologic system should be used for cancers that occur in older
adolescents and young adults to take account of the unique
features in this age group.
The morphology-based scheme presented above has been devel-
oped speciﬁcally for the 15 to 24 year age range and the diagnostic
groups reﬂect the numerical importance of cancers observed. A
number of the deﬁned groups in the above scheme are comparable
to the equivalent groups in the childhood cancer classiﬁcations and
Birch and Marsden, 1987; Kramarova and Stiller, 1996) thereby
facilitating comparisons of rates in children with those in adoles-
cents and young adults. However, it would also be of interest to
apply the scheme to cancers in children aged 10–14 years, since
in this age group embryonal tumours are relatively rare.
We should like to propose the use of this classiﬁcation scheme
in future studies of cancers in adolescents and young adults to
achieve a standard format for presentation of such data, to facili-
tate international comparisons, and to encourage an interest in
research into these cancers.
In children aged less than 15 years, 33% of all malignancies are
leukaemias, 25% are CNS tumours, 9% are lymphomas, 9% are
bone and soft tissue sarcomas, and childhood embryonal tumours
(neuroblastoma, retinoblastoma, Wilms’ tumour and hepatoblasto-
ma), comprise 16%. Less than 2% of childhood cancers are
carcinomas (McNally et al, 2001a,b). It can be seen (Table 3) that
the distribution of cancer types among the 15 to 19 year olds
represents a transitional pattern between that seen in children
and the pattern seen in the 20 to 24-year-olds which is somewhat
more typical of older ages. In both age groups, lymphomas have
the highest rates, but whereas leukaemia has the second highest
rate in the younger group, it drops to ﬁfth in the older group.
Similarly, CNS tumours and bone tumours also drop in rank order
in the older group but carcinomas, germ cell tumours and melano-
ma increase in numerical importance. Childhood embryonal
tumours comprised only 0.3% of all cancers in the 15–24 year
age range.
In 15 to 24-year-olds, carcinomas represent 17% of total regis-
trations but the primary site distribution is very different from
that seen at older ages. Across all ages, cancers of lung, colon
and rectum together, represent 28% of all malignancies (Quinn
et al, 2001), but only 2% of malignancies in 15 to 24-year-olds
are carcinomas of these sites. In contrast, in 15 to 24-year-olds,
melanoma and carcinoma of the thyroid represent 8 and 3% of
all cancers respectively, but across all ages these cancers make up
only 2 and 0.4% of the total. One of the most striking patterns
was the more than three-fold increase in incidence rates with age
for germ cell tumours in males, largely due to testicular teratoma
and seminoma. The incidence of testicular cancer overall continues
to rise reaching a peak of around 130 per million in men aged 30
to 34, after which there is a sharp decline in rates with age (Quinn
et al, 2001).
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in females is similar in both the 15–19 year age group and the
20–24 year age group and is also similar to that found in children
aged 10–14 years (McNally et al, 2001a,b; Stiller et al, 1998). Over-
all, and in most groups, rates were higher in males than females. In
certain diagnostic groups however, the sex ratio differed in the two
age groups notably germ cell tumours in which the rates in males
increased markedly in the older group. This contrasts with the
pattern in children where there is a higher rate of germ cell
tumours in children aged 10–14 years. The noticably higher rate
of melanoma in females in both the 15–19-year-olds and the
20–24-year-olds is not seen in 10–14-year-olds, but the overall
rates are very much lower in the latter age group (McNally et al,
2001a; Stiller et al, 1998). Other groups showing marked increases
in rates with age in females include carcinomas of thyroid, breast
and GU tract. These cancers are extremely rare in children but a
female excess of carcinoma of the thyroid in children is neverthe-
less apparent (Stiller et al, 1998). Another of the more marked
changes with age occurs in HD. In children aged 10–14 the male
to female ratio for HD is 1.8 (McNally et al, 2001b). In adolescents
and young adults this ratio becomes 1.0. This change in the sex
ratio in HD may reﬂect differing aetiologies and proportions of
sub-types at different ages.
When incidence rates in the two age groups combined were
examined for trends over time, marked increases in rates were seen
for all cancers together in the second and third periods. The largest
increases were seen for melanoma of skin, where the incidence
doubled from the earliest period to the latest period, and in
germ-cell tumours, which increased by 50%. There were also highly
signiﬁcant increases in the incidence of NHL, CNS tumours and
certain carcinomas.
Increases in the incidence of melanoma of skin and testicular
cancer in young adults have been noted previously (Quinn et
al, 2001) but although increases in the incidence of NHL have
been described (Quinn et al, 2001; McNally et al, 1999) these
were accounted for mainly by disease occurrence at older ages.
There was no change in rates for HD and while there was a small
increase in AML, there was no change in the incidence of ALL.
These trends for leukaemias and lymphomas contrast with those
recently reported in children where there were signiﬁcant increases
in ALL and HD but stable rates for AML and NHL (McNally et
al, 2001b). In ALL the increase in children was due to B-cell
precursor disease and in HD the rise was accounted for by the
nodular sclerosis sub-type. It is not possible to examine trends
by sub-type in the current data since information on immuno-
phenotype is not available and a large number (32%) of HD
cases were not coded to a speciﬁc sub-type. However, the overall
contrasting patterns in incidence trends suggest differences in
aetiology among leukaemias and lymphomas in children, adoles-
cents and young adults.
When CNS tumours were analysed by sub-type, the overall
increase was found to be due to astrocytic tumours and miscella-
neous brain tumours. There was a decrease in the ‘other glioma’
group and some, but not all of the increase in astrocytomas may
be due to more speciﬁc classiﬁcation of these other gliomas. The
trend in astrocytoma is consistent with that recently reported for
astrocytomas in children and common aetiological factors may
be operating (McNally et al, 2001a). Further examination of the
increase in miscellaneous brain tumours showed that the increase
was accounted for by unspeciﬁed tumours from 1988 onwards.
This may be due to additional cases being diagnosed as a result
of better radiological techniques.
We observed an increase in the rates for thyroid carcinoma,
particularly in females (data not shown). An increased incidence
for thyroid cancer in young adults, has been noted before (Cotterill
et al, 2001). Concern was raised that this may be related to radio-
active fall-out from the Chernobyl accident, but the observed
pattern of thyroid cancer incidence is inconsistent with this inter-
pretation (Stiller, 2001). It has also been suggested that thyroid
cancer is negatively associated with cigarette smoking. The higher
rates in women were said to be due to lower rates of cigarette
smoking compared with men (Kreiger and Parkes, 2000). However,
this putative association would not account for the trends observed
in the present study.
It is interesting to note the signiﬁcantly increasing incidence of
ovarian carcinoma in young women (data not shown) given the
highly signiﬁcant increase in testicular germ cell tumours but no
comparable increase in ovarian germ cell tumours. Most of the
observed increase in ovarian carcinomas occurred during the
1993–1997 period. The data for 1995–1997 were coded according
to ICD-O2 which includes certain tumours classiﬁed as malignant
which were formerly assigned to the ‘uncertain behaviour’ category
in ICD-O1. We therefore examined the ovarian carcinoma data for
the relevant codes. There were 48 such cases and if these are
removed from the data, the trend is no longer signiﬁcant. A similar
observation was made for data on patients aged 15–19 years with
ovarian carcinoma who were included in the SEER programme
(Smith et al, 1999). The apparent increase in the incidence of ovar-
ian carcinoma in adolescent and young adult women in England
may therefore be artefactual. However, the coding changes may
also reﬂect changes in diagnostic practice among pathologists and
it is not certain that the 48 tumours would have been coded as
having ‘uncertain behaviour’ in earlier years.
Among soft tissue sarcomas, ﬁbromatous tumours showed a
decrease in incidence but there was a corresponding rise in the
incidence of miscellaneous soft tissue sarcomas. The observed trend
in both of these groups is almost certainly due to changes in histo-
pathological classiﬁcation. The terms ﬁbrosarcoma and ﬁbrous
histiocytoma are applied much more stringently in current histo-
pathological practice than in the past. With the development of
immunohistochemical techniques it is now possible to classify soft
tissue sarcomas more precisely (Weiss and Goldblum, 2001).
The rates shown in Table 3 are largely consistent with those
found in a small study in this age group in the Northern Region
of England and which partially overlaps with the present study
(Cotterill et al, 2000). However, the Northern Region study
included less than one tenth the number of cases in the present
study and variations in rates with respect to diagnostic sub-groups
are probably due to the very small numbers resulting in unstable
rates for a number of the groups. For example, the rate for rhab-
domyosarcoma in the Northern Region in 20–24-year-olds was
reported as 0.8 per million compared with 1.4 per million in the
present study, but the former rate was based on only ﬁve cases.
In a more substantial series of cancers in 15–19-year-olds included
in the SEER Programme, Smith et al (1999) found an overall
cancer rate of 202 per million compared with 144 in the present
study. Rates for leukaemia, HD and rhabdomyosarcoma were very
similar but higher rates for most other cancers were seen in the
SEER data. This was particularly marked for germ cell tumours,
thyroid carcinoma and malignant melanoma. These are all cancers
which have shown increases in incidence over time (Table 4 and
Smith et al, 1999) which may well be related to changes in
socio-economic and lifestyle factors. Such effects may have been
operating in the United States earlier than in England resulting
in the higher rates in the SEER series.
In conclusion, we have devised a classiﬁcation scheme speciﬁ-
cally tailored to cancers in adolescents and young adults which
we hope will be used by others. The management of cancer in this
age group should address patients’ requirements for further and
higher education, vocational and professional training, social and
career development and possible long term treatment-related
morbidity including preservation of fertility (Lewis, 1996). The
data presented on cancer incidence will provide a basis for service
planning, including support services for survivors, which will
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data, in particular the increasing incidence trends in speciﬁc diag-
noses, will stimulate interest in devising targeted studies among
young cancer patients. Future studies should focus on possible
aetiological factors.
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